Memorial Sloan Kettering Cancer Center

- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
- First Posted Date
- 2012-05-28
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT01606787
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
- Conditions
- Brain Cancer
- Interventions
- Diagnostic Test: MRI perfusion and PET/CT scans
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 148
- Registration Number
- NCT01604512
- Locations
- πΊπΈ
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Commack, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Food: A Three-Arm Study Examining Food Insecurity Interventions
- Conditions
- Cancer Patients
- Interventions
- Behavioral: surveysBehavioral: Focus groups
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 668
- Registration Number
- NCT01603316
- Locations
- πΊπΈ
Brooklyn Hospital Center, Brooklyn, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈQueens Hospital Center, Jamaica, New York, United States
Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
- Conditions
- Pancreatic Neuroendocrine Cancer
- Interventions
- Other: MRI
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT01603004
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
- Conditions
- Acute LeukemiaChronic LeukemiaMyelodysplastic SyndromeNon-Hodgkins Lymphoma
- Interventions
- Radiation: total-body irradiation (TBI)Biological: anti-thymocyte globulinProcedure: allogeneic hematopoietic stem cell transplantationBiological: peripheral blood stem cell transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01598025
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
- Conditions
- Liver Cancer
- Interventions
- Procedure: Standard fluid managementDevice: Goal directed fluid therapy with the Edwards EV1000 system
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 135
- Registration Number
- NCT01596283
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation
- Conditions
- Leukemia
- Interventions
- Procedure: allogeneic hematopoietic stem cell transplantationDevice: CliniMACS
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT01596257
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPeritoneal Cancer
- Interventions
- Other: Neuroimaging & Neuropsychological Evaluation
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT01591772
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT01589094
- Locations
- πΊπΈ
University of North Carolina, Chapel Hill, North Carolina, United States
πΊπΈMemoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Renal Cancer
- Interventions
- Drug: 124IcG250
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01582204
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States